The New England Journal of Medicine
HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   HELP   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
* This Week in the Journal
 May 15, 2008
 Audio Icon Audio Summary
*
Correspondence
* Mild Traumatic Brain Injury in U.S. Soldiers Returning from Iraq
* Outcomes 18 Months after the First Human Partial Face Transplantation
* Selective Publication of Antidepressant Trials
* Physicians and Execution
* Perspective Roundtable: Lethal Injection
* Letting the Genome Out of the Bottle
* Serotonin Syndrome Associated with Triptan Monotherapy
*
Book Reviews
* The Longevity Revolution: The Benefits and Challenges of Living a Long Life
* Fundamentals of the Stem Cell Debate: The Scientific, Religious, Ethical and Political Issues
* Sex Differences in the Brain: From Genes to Behavior
*
Continuing Medical Examination
* Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
* Cardiac Troponin and Outcome in Acute Heart Failure
* Case 15-2008: A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer
Original Articles
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

Several regimens are used as initial antiretroviral therapy for HIV-1 infection, but few direct comparisons are available. In this randomized, open-label study, efavirenz plus two nucleoside reverse-transcriptase inhibitors (NRTIs), lopinavir–ritonavir plus two NRTIs, and lopinavir–ritonavir plus efavirenz were compared. Initial therapy with efavirenz plus two NRTIs was associated with less virologic failure than was lopinavir–ritonavir plus two NRTIs. The NRTI-sparing regimen of lopinavir–ritonavir plus efavirenz had virologic efficacy similar to that of efavirenz plus two NRTIs but was more likely to select for drug resistance.

Related Editorial


Original Articles
Biomarkers to Predict Death from Cardiovascular Causes

To predict the risk of death from cardiovascular causes in a community-based cohort of elderly men, the authors used a combination of biomarkers (troponin I, N-terminal pro–brain natriuretic peptide, cystatin C, and C-reactive protein). The addition of these markers to a model with traditional cardiovascular risk factors significantly improved risk stratification as compared with a model that used only the traditional risk factors.

Related Editorial


Original Articles
Cardiac Troponin in Acute Heart Failure

In this large, retrospective registry study, patients hospitalized with acute decompensated heart failure who had elevated cardiac troponin levels had higher mortality rates than those who were negative for troponin, even after correction for other predictive variables. Measurement of cardiac troponin, which may reflect myocyte injury, is useful for risk stratification of such patients.


Original Articles
Recombinant Factor VIIa for Intracerebral Hemorrhage

In a previous phase 2 placebo-controlled trial, recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcome in patients with intracerebral hemorrhage. Those findings were not reproduced in this phase 3 trial, in which rFVIIa reduced hematoma growth but did not improve clinical outcomes.

Related Editorial


Clinical Practice
Rotator-Cuff Failure

A 63-year-old woman presents with a 2-year history of progressive weakness and discomfort in her right shoulder, especially when she puts dishes on the top shelf in her kitchen. She is otherwise healthy and has had no injuries. Physical examination shows some atrophy of the muscles in the right shoulder and weakness when the right arm is elevated. Magnetic resonance imaging shows a large defect in the rotator cuff. How should her case be managed?


Review Article
Medical Progress: Biomarkers in Heart Failure

Heart failure results not only from cardiac overload or injury but also from a complex interplay among genetic, neurohormonal, inflammatory, and biochemical changes acting on cardiac myocytes, the cardiac interstitium, or both. This review focuses on biomarkers for heart failure other than routinely determined laboratory values and discusses how these might be used in assessing and managing heart failure.


Case Records of the Massachusetts General Hospital
A 55-Year-Old Man with an Elevated PSA Level and Early-Stage Prostate Cancer

A 55-year-old man was referred to this hospital for management of prostate cancer. An elevated serum prostate specific antigen (PSA) level was found during evaluation of urinary symptoms; core needle biopsies of the prostate disclosed adenocarcinoma, with a Gleason score of 6 out of 10. Examination and computed tomography showed a smoothly enlarged prostate and no lymphadenopathy. Options for management were discussed.


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.